slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 6,421-6,450
Pages 296
Rows per page 30
Slide type
6,421-6,450 of 8,880
72
The slide uses two distinct chart types (dot plot and line chart with error bars) to illustrate the safety profile of the drug candidate '539.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
74
The slide uses a heatmap to visualize synergy (green = yes, light green = no) across 6 drug combinations and 14 patient samples.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
76
Uses Bliss Independence Model for synergy calculation. Includes a heatmap of synergy across subtypes and dose-response curves for two specific models (DMS79 and H345).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
78
The slide uses a two-column layout to contrast PK and Toxicology findings.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 1 hit
81
The slide uses a three-column layout to summarize the value proposition of a drug candidate.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 1 hit
82
The slide uses a biological pathway diagram to illustrate the mechanism of action.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 1 hit
83
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 1 hit
87
The slide highlights the application of computational chemistry (molecular dynamics) to drug discovery, specifically focusing on binding site analysis.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations 1 hit
10
Uses the 'argument-from-analogy' framework by comparing their business model to Amadeus/Sabre and Booking.com/Expedia.Freightos | Investor Presentation Deck | 37 slides · Freightos
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
10
The slide uses a four-column layout to present key benefits.Hagerty | Investor Presentation Deck | 19 slides · Hagerty
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a bar chart to visually demonstrate the scale of their 'clean' ingredient policy compared to industry standards.Honest | Investor Presentation Deck | 31 slides · Honest
Pitch deck Investor relations Beat · Rising Success1 hit
22
Honest | Investor Presentation Deck | 31 slidesHonest | Investor Presentation Deck | 31 slides · Honest
Pitch deck Investor relations Beat · Ultimate AchievementLoop · Why Now1 hit
07
The slide uses a structural diagram to map technical modifications to clinical outcomes.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
Includes a biological pathway diagram showing B-cell maturation and a pyramid diagram showing the hierarchy of disease targeting.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
Includes a biological process diagram showing the interaction between NXC-201 CAR-T cells and disease-causing LLPC clones.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Includes dot plot for BCMA expression, bar chart for IFNy activation, and flow cytometry plots showing cell elimination.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and exhaustion.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
Includes citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
Uses a combination of bar charts for preclinical data and a comparison table for clinical outcomes to demonstrate the superiority of the CD8 hinge optimization.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
The slide uses a schematic to compare HSL and LSH configurations, showing superior performance for HSL in expansion and cytotoxicity metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
25
The slide uses a comparative diagram to show structural differences between NXC-201 and Abecma.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
31
The slide uses a structural layout to map platform capabilities to specific therapeutic products.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
Includes a process diagram illustrating the medical procedure and a list of key attributes.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
44
The slide uses a hub-and-spoke style diagram to link the platform pillars to specific drug candidates.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
46
Includes three distinct proof-of-concept data panels (penetration, biodistribution, apoptosis).Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
51
The slide uses a standard biological signaling pathway map to demonstrate the mechanism of action of the drug candidate.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
53
Includes a comparison of iMX-111 size vs IgG antibody, GLUT1 expression across tissues, correlation with cancer stage, and a survival curve.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
54
The slide uses a combination of mechanism diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
08
The slide uses a hub-and-spoke style diagram with a central image of two vehicles surrounded by seven service pillars.Lion Electric | Investor Presentation Deck | 32 slides · Lion Electric
Pitch deck Investor relations Beat · ProductLoop · Quick Win Big Bet1 hit
04
Includes scientific illustration of molecular structure and bulleted list of key benefits.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit